Core Viewpoint - The average stock price of the Sci-Tech Innovation Board is 38.12 yuan, with 62 stocks priced over 100 yuan, indicating a strong performance in the market [1][2]. Stock Performance - A total of 520 stocks on the Sci-Tech Innovation Board rose today, while 68 fell, with the highest closing price being 1261.98 yuan for Cambrian-U, which increased by 1.04% [1]. - Among the stocks priced over 100 yuan, the average increase was 1.98%, with notable gainers including Tengjing Technology and Pinming Technology [1][2]. - The latest closing prices of stocks relative to their issue prices show an average premium of 511.77%, with the highest premiums for companies like Shuangwei New Materials and Cambrian-U [1]. Industry Distribution - The stocks priced over 100 yuan are concentrated in the electronics, pharmaceutical, and computer industries, with 31, 9, and 8 stocks respectively [1]. Capital Flow - There was a net outflow of 10.89 billion yuan from the main funds in the stocks priced over 100 yuan, with notable inflows into companies like Zhongwei Company and Kingsoft [2]. - The total margin financing balance for stocks priced over 100 yuan is 848.48 billion yuan, with Cambrian-U and Zhongxin International having the highest financing balances [2]. Stock List - A detailed list of stocks priced over 100 yuan includes Cambrian-U at 1261.98 yuan, Yuanjie Technology at 521.00 yuan, and GuoDun Quantum at 437.98 yuan, among others, showcasing their respective price changes and industry classifications [2][3][4].

Group 1 - The technology sector shows a mixed performance today, with AI applications leading the gains while semiconductor hardware and solid-state battery sectors experienced a pullback in the afternoon [1] - The Sci-Tech Innovation Composite Index rose by 1.7%, the Sci-Tech Growth Index increased by 1.4%, the Sci-Tech 100 Index went up by 1.3%, and the Sci-Tech 50 Index gained 0.8% [1] Group 2 - Small innovative enterprises in the fields of electronics, biomedicine, and power equipment account for over 80% of the sector, with a significant representation from the electronics and biomedicine industries [5] - The Sci-Tech Composite Index ETF by E Fund tracks the comprehensive index of the Sci-Tech Innovation Board, covering all market securities and focusing on core industries such as artificial intelligence, semiconductors, new energy, and innovative pharmaceuticals [7] - The Sci-Tech Growth 50 ETF tracks the growth index of the Sci-Tech Innovation Board, consisting of 50 stocks with high growth rates in revenue and net profit, predominantly from the electronics and biomedicine sectors [7]

Core Insights - The pharmaceutical MNC supply chain has extremely high entry barriers, requiring years for supplier certification through cross-departmental audits in technology, quality, EHS, and compliance. Once included in the qualified supplier list, a strong lock-in effect is formed, making it difficult for new entrants to disrupt the existing supply structure even if they meet technical standards, thus demonstrating a strong first-mover advantage [4][7]. - MNCs demand far more than conventional quality compliance, emphasizing full-process controllability and risk management capabilities. Compliance with guidelines such as EU GMP and ICHQ is required, along with the establishment of traceability systems and safety stock. Any process changes or relocation of production sites must undergo strict and time-consuming certification [4][7]. - In procurement decisions, MNCs are relatively insensitive to price factors, prioritizing the integrity of the supply chain over cost. For MNCs, API costs represent only a small portion of their terminal formulation sales, leading them to pay a premium for stable, traceable, and zero major quality incident supply capabilities, viewing supply chain resilience as a core competitive advantage rather than a cost item. Thus, entering the MNC supply chain often means effectively avoiding "price internalization" [4][7]. - Investment recommendations include innovative drug and device companies such as Furuya Co., Aonlikang, Shutaishen, Weichuang Bio, and others. From the perspective of CXO and raw materials, companies like WuXi AppTec, Jiuzhou Pharmaceutical, Chengda Pharmaceutical, and others are suggested for attention [4][7]. Market Performance Overview - As of November 21, 2025, the TTM-PE of the pharmaceutical and biotechnology industry is 48.84 times, which is 100% higher than the historical lowest PE valuation of 24.38 times on January 3, 2019. The premium rate relative to the CSI 300 is 252%, exceeding the historical lowest valuation premium of 124% on February 6, 2018, by 128 percentage points, and is 11 percentage points higher than the average valuation premium rate of 241% over the past decade [8][12]. - From November 17 to November 21, 2025, the pharmaceutical and biotechnology sector experienced a decline of 6.88%, ranking 22nd among 27 sub-industries. The chemical raw materials sector saw the largest decline at -8.60% [12][15]. Industry Dynamics - Pfizer's Class 1 new drug, Matacizumab, was approved for marketing on November 21, 2025, for the routine prevention and treatment of bleeding in patients with severe hemophilia A or B [20]. - Boehringer Ingelheim's Class 1 new drug, BI764198, was proposed for inclusion as a breakthrough therapy on November 18, 2025, targeting primary focal segmental glomerulosclerosis [21]. - The PD-1 inhibitor H drug, Surulutumab, developed by Fuhong Hanlin, was officially included as a breakthrough therapy on November 20, 2025, for gastric cancer treatment [22]. - On November 17, 2025, FDA approved the biosimilar of Tysabri, developed by Sandoz, for multiple sclerosis and Crohn's disease [23].

Volatility - A total of 13 stocks in the A-share market experienced a volatility exceeding 20% today, with Meideng Technology, Jianglong Shipbuilding, and Jiuzhiyang leading the list [1] Turnover Rate - There were 7 stocks in the A-share market with a turnover rate exceeding 40% today, with Rongji Software, Southern Road Machinery, and Jianglong Shipbuilding at the forefront [1] Main Capital Flow - Main capital today saw a net inflow into sectors such as defense and military, media, retail, construction decoration, public utilities, and banking, while there was a net outflow from electronics, computers, power equipment, basic chemicals, communications, and biomedicine [1] - The stocks with the highest net inflow included BlueFocus Communication Group, Shengguang Group, Aerospace Development, Dataport, and Midea Group, with net inflows of 1.344 billion, 738 million, 446 million, 397 million, and 347 million respectively [1] - The stocks with the highest net outflow included Xinyi Technology, Zhongji Xuchuang, Industrial Fulian, Rongji Software, and Yidian Tianxia, with net outflows of 1.177 billion, 1.126 billion, 883 million, 878 million, and 835 million respectively [1]

每经记者｜汤辉 文多 每经编辑｜文多 程鹏 2020年的年报季已经结束，在疫情的冲击下，多数A股上市公司却交出了让投资人惊喜的答卷。这3580份年报中，有255份是80后、90后董事长交出的 ——我们将他们称之为青年董事长。 在经过数据梳理后，我们发现，这些青年董事长的情况，与刻板的印象、先入为主的想象相去甚远。 你以为青年董事长们，都是电子商务达人？让人意外的是，医药行业的青年董事长最多； 你觉得最赚钱的青年董事长年薪是多少。但现实里，怎么有的青年董事长，薪酬还不如打工人？ 五四青年节，来听听A股青年董事长的故事。 青年董事长素描A：30岁以下董事长8位，特点接近 截至A股各上市公司2020年年报披露日，41岁及以下的董事长——也就是80后、90后有255位。 这在超过4000家上市公司中，占比已经接近6%。 80后、85后、90后、95后，各年龄段的董事长人数基本保持了递减的规律。因此，这其中的半壁江山还是1980~1984年生人，达到了167位。 图片来源：摄图网 制图：汤辉 这些董事长在人数上以深市最多。 制图：汤辉 另外，创业板的青年董事长在该板块所有董事长中占比几近7%，高于A股整体水平（约6%） ...

Group 1 - The core index tracks 50 stocks from the Sci-Tech Innovation Board with high growth rates in revenue and net profit, emphasizing a growth style [3] - The electronic and pharmaceutical industries account for nearly 75% of the index's composition, indicating a strong presence of high-growth sectors [3] - As of the latest trading session, the index experienced a slight increase of 0.1% and has a rolling price-to-earnings ratio of 142.3 times [3] Group 2 - The index was officially launched on July 23, 2020, and is part of a broader set of indices including the Sci-Tech Innovation 100 Index and the Sci-Tech Innovation Comprehensive Index [4] - The rolling price-to-earnings ratio is calculated as total market value divided by net profit, which is a relevant valuation metric for stable industries less affected by economic cycles [4] - The fund products associated with this index have low management fees of 0.15% per year and custody fees of 0.05% per year, making them attractive for investors [4]

中信建投证券表示，当前市场处于"三期叠加"：牛市中段整固期，景气验证关键期，业绩政策空窗期， 市场震荡轮动和资金年底止盈等特征也会进一步放大。近期海外环境出现较多扰动，美联储12月降息预 期反复，带动全球市场流动性预期波动；英伟达财报超预期，但股价出现巨震，投资者担忧AI开支可 持续性，蔓延影响A股情绪。长期而言，慢牛格局的主要因素不变；短期来看，策略层面以择机布局为 主，时点上等待12月中上旬的美联储议息会议和中央经济工作会议落地，其间若调整较充分也可加仓吸 筹，关注60日线与半年线支撑和市场缩量情况。 24日早盘，两市主要股指盘中震荡回落，创业板指盘中跌约1%失守2900点，场内约3200股飘红。 盘面上看，煤炭、燃气、有色、电力、保险等板块走低，军工、医药等板块逆市拉升，军贸概念、AI 应用概念等活跃。 截至午间收盘，沪指跌0.34%报3821.68点，深证成指跌0.59%，创业板指跌0.77%，沪深北三市合计成交 10326亿元。 ...

11月24日，香港恒生指数开盘涨0.92%，恒生科技指数涨1.13%。 | 代码 | 名称 | 现价 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | HSI | 恒生指数 | 25452.87 232.85 | 0.92% | | HSTECH 恒生科技 | | 5456.61c 61.12 1.13% | | | HSBIO | 恒生生物科技 | 15167.07c 148.28 | 0.99% | | HSCEI | 恒生中国企业指数 | 8991.62c 71.84 | 0.81% | | HSCI | 恒生综合指数 | 3893.05c 31.93 | 0.83% | 零跑汽车涨超3%，该股纳入恒生科技指数，12月8日起生效。 编辑丨瑜见 | < W | 恒生科技(HSTECH) | | | | --- | --- | --- | --- | | | 5456.61 61.12 1.13% | | | | 资料 成分 | 资讯 相关基金 | | 月度收益 | | 名称 | | 现价 | 涨跌幅 == | | 蔚来-SW | | 44.900 | 4.52% | | 986 ...

A-shares - Nobikang Artificial Intelligence Technology (Chengdu) Co., Ltd. has submitted its third listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [2] - As of November 17, over 10,000 new private equity securities investment funds have been registered this year, with stock strategies being the dominant force in the issuance market [2][3] - In November, 509 overseas institutions conducted research on 109 listed companies, with a focus on the electronics and machinery equipment sectors [2] Financial Products - As of November 20, 19 insurance companies have issued capital replenishment bonds or perpetual bonds this year, totaling over 70 billion yuan, with nearly 70% being perpetual bonds [4] - The latest LPR remains unchanged at 3.0% for 1-year and 3.5% for 5-year terms, maintaining stability for six consecutive months [4] - The Shanghai and Shenzhen Stock Exchanges have released new guidelines to promote high-quality development of index investment [4] Fund Market - As of November 17, a total of 1,378 public funds have been issued this year, surpassing last year's total of 1,143, marking the highest issuance in three years [5] - The average subscription period for new funds has decreased from 22.63 days last year to 16.31 days this year, indicating increased market activity [5] Economic Indicators - In October, China's retail sales grew by 2.8%, with significant increases in the sales of upgraded consumer goods such as gold and jewelry, which rose by 37.6% [6][7] - From January to October, the national general public budget revenue reached 18.65 trillion yuan, a year-on-year increase of 0.8%, while expenditure was 22.58 trillion yuan, up 2% [8]

Market Overview - The U.S. stock market did not experience a continued decline, with major indices rebounding significantly [1] - Concerns regarding liquidity issues were primarily driven by the Federal Reserve's statements, leading to global market volatility [1][6] - The recent fluctuations in technology stock valuations have contributed to increased market volatility and a decline in risk appetite [1][6] Technical Analysis - The Shanghai Composite Index has a downward support level projected between 3800-3810 [3][7] - The ChiNext Index has a downward support level projected between 2500-2530 [3][7] - The market is currently in a phase of adjustment, with a focus on identifying potential buy signals [6] Investment Strategy - The current recommendation is to maintain a cautious approach and wait for stabilization signals before entering the market [5][10] - Short-term buying opportunities may arise during panic selling, but a low position is advised [5][6] - The focus should be on sectors such as banking for blue-chip stocks, pharmaceuticals for potential rebounds, and renewable energy for price increase opportunities [7] Market Sentiment - The overall sentiment indicates that risks currently outweigh opportunities, with a cautious outlook on market movements [6][10] - The market is experiencing a phase of risk release, and investors are advised to either refrain from trading or wait for clear signals of stabilization [10]